---
title: "CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296433558.md"
description: "CSPC Pharma reported FY26 H1 results with revenue surging 40.1% to RMB 18.59 billion and net profit more than doubling to RMB 6.09 billion. Finished drug revenue climbed 56.7% to RMB 16.06 billion, driven by license fees, while bulk products declined. The company raised its interim dividend to HK 18 cents per share and allocated HKD 321 million for share buybacks."
datetime: "2026-08-20T04:19:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296433558.md)
  - [en](https://longbridge.com/en/news/296433558.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296433558.md)
generator: "portal-rs"
---

# CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion

-   CSPC Pharmaceutical posted first-half revenue of RMB 18.59 billion, up 40.1% year over year. \* Profit attributable to shareholders more than doubled to RMB 6.09 billion, lifting basic EPS 139.8% to RMB 53.45 cents. \* Finished drugs revenue climbed 56.7% to RMB 16.06 billion, helped by licence fee income of RMB 5.89 billion. \* Bulk products revenue fell 20% to RMB 1.66 billion; functional food and others slipped 8.2% to RMB 873.4 million. \* Interim dividend raised to HK 18 cents per share; HKD 321 million used to buy 46,178,000 shares for awards. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12292007), on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [UBS Raises CSPC PHARMA  TP to HKD11.8, Reiterates Buy](https://longbridge.com/en/news/296585459.md)
- [Citi Raises CSPC PHARMA  TP to HKD14, Rating Buy](https://longbridge.com/en/news/296566031.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**